KR20010071237A - 엑테인아시딘 743의 대사산물 - Google Patents
엑테인아시딘 743의 대사산물 Download PDFInfo
- Publication number
- KR20010071237A KR20010071237A KR1020007012616A KR20007012616A KR20010071237A KR 20010071237 A KR20010071237 A KR 20010071237A KR 1020007012616 A KR1020007012616 A KR 1020007012616A KR 20007012616 A KR20007012616 A KR 20007012616A KR 20010071237 A KR20010071237 A KR 20010071237A
- Authority
- KR
- South Korea
- Prior art keywords
- etm
- patient
- administering
- effective amount
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/10—Quaternary compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
| ID # | 시험관 # | Rf a | 중량 | L1210500 ng/mL에서성장 저해(%) |
| ETM-SiOH 1 | 1 | 0.9 | 2.0 mg | 0 |
| ETM-SiOH 2 | 2 | 0.5, 0.7 | 0.3 mg | 80b |
| ETM-SiOH 3 | 4-5 | 0.5 | 0.4 mg | 30 |
| ETM-SiOH 4 | 6 | 0.3 | 0.2 mg | 3 |
| 세포주 & 활성IC50(ug/ml) | ||||
| 화합물 | P-388 | A-549 | HT-29 | MEL-28 |
| ETM-305 | 0.5 | 0.5 | 0.5 | 0.25 |
| ETM-775 | 0.01 | 0.01 | 0.01 | 0.01 |
Claims (14)
- 다음 구조를 갖는, 실질적으로 순수한 ETM-305:
- 다음 구조를 갖는, 실질적으로 순수한 ETM-204:
- 다음 구조를 갖는, 실질적으로 순수한 ETM-775:
- 환자에 단위 투여형태로 유효량의 ETM-305를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 백혈병의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-775를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 백혈병의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-305를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 폐 암종의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-775를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 폐 암종의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-305를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 결장 선암종의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-775를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 결장 선암종의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-305를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 악성 흑색종의 치료 방법.
- 환자에 단위 투여형태로 유효량의 ETM-775를 투여하는 것을 포함하는, 그러한 치료가 필요한 환자에서 포유동물 악성 흑색종의 치료 방법.
- ETM-305 및 약학적으로 허용되는 담체, 희석제 또는 부형제를 포함하는 약학적 조성물.
- ETM-775 및 약학적으로 허용되는 담체, 희석제 또는 부형제를 포함하는 약학적 조성물.
- ETM-204, ETM-305 및 ETM-775로 구성된 군에서 선택된 하나 이상의 대사산물의 존재에 대해 시험 샘플을 모니터하는 것을 포함하는, 엑테인아시딘 743의 인간 사이토크롬 CYP3A4 대사의 측정 방법.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8502498P | 1998-05-11 | 1998-05-11 | |
| US60/085,024 | 1998-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010071237A true KR20010071237A (ko) | 2001-07-28 |
| KR100643092B1 KR100643092B1 (ko) | 2006-11-10 |
Family
ID=22188976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007012616A Expired - Fee Related KR100643092B1 (ko) | 1998-05-11 | 1999-05-11 | 엑테인아시딘 743의 대사산물 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US6316214B1 (ko) |
| EP (1) | EP1077698B1 (ko) |
| JP (2) | JP4583598B2 (ko) |
| KR (1) | KR100643092B1 (ko) |
| CN (3) | CN100339375C (ko) |
| AT (1) | ATE289810T1 (ko) |
| AU (1) | AU759281B2 (ko) |
| BG (1) | BG65235B1 (ko) |
| BR (1) | BR9910419A (ko) |
| CA (1) | CA2331593C (ko) |
| CZ (1) | CZ302168B6 (ko) |
| DE (1) | DE69923965T2 (ko) |
| ES (1) | ES2239442T3 (ko) |
| HU (1) | HUP0101960A3 (ko) |
| IL (2) | IL139607A0 (ko) |
| NO (1) | NO318081B1 (ko) |
| NZ (1) | NZ508585A (ko) |
| PL (1) | PL192409B1 (ko) |
| RU (1) | RU2225864C2 (ko) |
| SK (1) | SK285069B6 (ko) |
| TR (1) | TR200003470T2 (ko) |
| WO (1) | WO1999058125A1 (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139607A0 (en) * | 1998-05-11 | 2002-02-10 | Pharma Mar Sa | Metabolites of ecteinascidin 743 |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| RU2266734C2 (ru) * | 1999-05-13 | 2005-12-27 | Фарма Мар, С.А. | Композиции и применение ет743 для лечения злокачественных опухолей |
| MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| KR100886496B1 (ko) | 2000-04-12 | 2009-03-05 | 파르마 마르, 에스.에이. | 항종양성 엑티나시딘 유도체 |
| US7919493B2 (en) * | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| JP2004529074A (ja) | 2000-11-03 | 2004-09-24 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | サフラマイシン、そのアナログ、およびその使用 |
| WO2002036135A2 (en) * | 2000-11-06 | 2002-05-10 | Pharma Mar, S.A. | Compositions for antitumour treatment containing ecteinascidin 743 |
| GB0117402D0 (en) | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0119243D0 (en) * | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| GB0202544D0 (en) * | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| US7407327B2 (en) * | 2003-03-21 | 2008-08-05 | Seagate Technology Llc | Method and system for withstanding shock in a spindle motor bearing |
| JP2007511499A (ja) | 2003-11-13 | 2007-05-10 | ファーマ・マール・エス・アー・ウー | コンビネーション |
| KR101188691B1 (ko) | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| RU2270536C9 (ru) * | 2004-12-01 | 2006-06-10 | Ооо "Твинн" | Свч плазмохимический реактор |
| US20090325971A1 (en) * | 2005-03-02 | 2009-12-31 | The Trustees Of Columbia University In The City Of New York | Pentacyclic Alkaloid Compounds and Methods of Use Thereof |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US20090012157A1 (en) | 2006-02-06 | 2009-01-08 | Sears Barry D | Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation |
| EP2786755A3 (en) | 2010-11-12 | 2014-10-29 | Pharma Mar S.A. | Combination therapy with an antitumor alkaloid |
| LT3615544T (lt) * | 2017-04-27 | 2023-05-10 | Pharma Mar S.A. | Priešnavikiniai junginiai |
| CA3158733A1 (en) | 2019-11-21 | 2021-05-27 | Pilar Calvo | Methods of treating small cell lung cancer with lurbinectedin formulations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4273773A (en) | 1979-09-24 | 1981-06-16 | American Home Products Corporation | Antihypertensive tricyclic isoindole derivatives |
| JPS59225189A (ja) | 1983-06-03 | 1984-12-18 | Shionogi & Co Ltd | キノナミン誘導体およびその製造法 |
| JPS6084288A (ja) | 1983-10-13 | 1985-05-13 | Shionogi & Co Ltd | シアノキノナミンアセテ−ト類およびその製造法 |
| US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5149804A (en) | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| EP0309477B1 (en) | 1986-06-09 | 1991-11-06 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759a, 759b and 770 |
| US5089273A (en) | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| TW221441B (ko) * | 1991-01-25 | 1994-03-01 | Taiho Pharmaceutical Co Ltd | |
| ATE158293T1 (de) | 1992-06-19 | 1997-10-15 | Hoechst Ag | Polycyclische 31668p- und 31668u-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als antibiotische oder antitumorale arzneistoffe |
| US5426108A (en) | 1993-11-10 | 1995-06-20 | American Cyanamid Company | Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2 |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5809563A (en) * | 1996-11-12 | 1998-09-15 | Institute For The Development Of Emerging Architectures, Llc | Method and apparatus utilizing a region based page table walk bit |
| US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| BR9909488B1 (pt) * | 1998-04-06 | 2011-02-08 | ecteinascidinas semi-sintéticas e composição farmacêutica. | |
| IL139607A0 (en) * | 1998-05-11 | 2002-02-10 | Pharma Mar Sa | Metabolites of ecteinascidin 743 |
| US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| MY130271A (en) | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| EP1254140A4 (en) * | 2000-01-19 | 2003-03-12 | Univ Columbia | SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USAGE AND SYNTHESIS THEREOF |
| KR100886496B1 (ko) | 2000-04-12 | 2009-03-05 | 파르마 마르, 에스.에이. | 항종양성 엑티나시딘 유도체 |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
-
1999
- 1999-05-11 IL IL13960799A patent/IL139607A0/xx active IP Right Grant
- 1999-05-11 WO PCT/US1999/010233 patent/WO1999058125A1/en not_active Ceased
- 1999-05-11 PL PL344183A patent/PL192409B1/pl not_active IP Right Cessation
- 1999-05-11 SK SK1715-2000A patent/SK285069B6/sk not_active IP Right Cessation
- 1999-05-11 JP JP2000547976A patent/JP4583598B2/ja not_active Expired - Fee Related
- 1999-05-11 AU AU40737/99A patent/AU759281B2/en not_active Ceased
- 1999-05-11 NZ NZ508585A patent/NZ508585A/xx unknown
- 1999-05-11 DE DE69923965T patent/DE69923965T2/de not_active Expired - Lifetime
- 1999-05-11 ES ES99924169T patent/ES2239442T3/es not_active Expired - Lifetime
- 1999-05-11 HU HU0101960A patent/HUP0101960A3/hu unknown
- 1999-05-11 CZ CZ20004183A patent/CZ302168B6/cs not_active IP Right Cessation
- 1999-05-11 TR TR2000/03470T patent/TR200003470T2/xx unknown
- 1999-05-11 EP EP99924169A patent/EP1077698B1/en not_active Expired - Lifetime
- 1999-05-11 BR BR9910419-9A patent/BR9910419A/pt not_active IP Right Cessation
- 1999-05-11 AT AT99924169T patent/ATE289810T1/de not_active IP Right Cessation
- 1999-05-11 CA CA002331593A patent/CA2331593C/en not_active Expired - Fee Related
- 1999-05-11 CN CNB2005100544181A patent/CN100339375C/zh not_active Expired - Fee Related
- 1999-05-11 KR KR1020007012616A patent/KR100643092B1/ko not_active Expired - Fee Related
- 1999-05-11 RU RU2000131178/04A patent/RU2225864C2/ru not_active IP Right Cessation
- 1999-05-11 CN CNB2006100944780A patent/CN100548988C/zh not_active Expired - Fee Related
- 1999-05-11 CN CNB998085200A patent/CN1195514C/zh not_active Expired - Fee Related
- 1999-05-11 US US09/309,947 patent/US6316214B1/en not_active Expired - Fee Related
-
2000
- 2000-11-10 NO NO20005671A patent/NO318081B1/no not_active IP Right Cessation
- 2000-11-10 IL IL139607A patent/IL139607A/en not_active IP Right Cessation
- 2000-12-05 BG BG105023A patent/BG65235B1/bg unknown
-
2001
- 2001-10-03 US US09/971,852 patent/US6867334B2/en not_active Expired - Fee Related
-
2004
- 2004-12-10 US US11/009,237 patent/US7115743B2/en not_active Expired - Fee Related
-
2010
- 2010-06-09 JP JP2010131960A patent/JP2010215656A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100643092B1 (ko) | 엑테인아시딘 743의 대사산물 | |
| US20090247533A1 (en) | Ecteinascidins | |
| US5654426A (en) | Ecteinascidins | |
| US5985876A (en) | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins | |
| US5149804A (en) | Ecteinascidins 736 and 722 | |
| EP1067933B1 (en) | Semi-synthetic ecteinascidins | |
| JPH02111772A (ja) | β―カルボリン類、ベンゾフラン類似体及びベンゾチオフェン類似体並びにこれらの調剤上許容される酸付加塩、β―カルボリン類、ベンゾフラン類似体及びベンゾチオフェン類似体を製造する方法、静細胞特性を有する組成物、腫瘍の治療方法 | |
| EP0251361A1 (en) | New di- and tetrahydroisoquinoline derivatives | |
| CN117586284A (zh) | 一种大环化合物及其制备方法与应用 | |
| US4590197A (en) | 9,10-substituted 2-mesitylimino-3-alkyl-3,4,6,7-tetra-hydro-2H-pyrimido(6,1-a)isoquinolin-4-ones, and their use as medicaments | |
| MXPA00011064A (en) | Metabolites of ecteinascidin 743 | |
| HK1033651B (en) | Semi-synthetic ecteinascidins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20101018 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20111101 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20111101 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |